China Resources Pharmaceutical Group Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 3/6
China Resources Pharmaceutical Group kazançlarla iyi bir şekilde karşılanan, 3.44% cari getiriye sahip, temettü ödeyen bir şirkettir.
Anahtar bilgiler
3.4%
Temettü verimi
4.8%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | 8.3% |
| Gelecekteki Temettü Verimi | 4.0% |
| Temettü Büyümesi | 13.6% |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | HK$0.184 |
| Ödeme oranı | 39% |
Son temettü ve geri alım güncellemeleri
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14Recent updates
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up
Oct 07Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Temettü ödemeleri istikrarlı olsa da 3320 10 yıldan az bir süredir temettü ödüyor.
Büyüyen Temettü: 3320 şirketinin temettü ödemeleri artmış, ancak şirket yalnızca 8 yıldır temettü ödemiştir.
Piyasaya Karşı Temettü Getirisi
| China Resources Pharmaceutical Group Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (3320) | 3.4% |
| Pazarın Alt %25'i (HK) | 3.3% |
| Pazarın En İyi %25'i (HK) | 8.1% |
| Sektör Ortalaması (Pharmaceuticals) | 3.7% |
| Analist tahmini (3320) (3 yıla kadar) | 4.0% |
Önemli Temettü: 3320 'in temettüsü ( 3.44% ), Hong Kong piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 3.28% ) daha yüksektir.
Yüksek Temettü: 3320 'in temettüsü ( 3.44% ), Hong Kong piyasasındaki temettü ödeyenlerin en üst %25'ine ( 8.05% ) kıyasla düşüktür.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Oldukça düşük ödeme oranı ( 39.4% ) ile 3320 'un temettü ödemeleri kazançlarla oldukça iyi bir şekilde karşılanıyor.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Düşük nakit ödeme oranı ( 6.8% ) sayesinde 3320 'un temettü ödemeleri nakit akışları tarafından tamamen karşılanmaktadır.